Key result
Real-world edoxaban shows low ~4% VTE recurrence and minimal major bleeding over 18 months.
Why the study?
The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism in clinical practice are not well understood.
What are the real-world rates of recurrent VTE, major bleeding, and all-cause death in unselected patients with VTE treated with edoxaban for up to 18 months?
Observational (n=2,644)
Yes
What are the real-world rates of recurrent VTE, major bleeding, and all-cause death in unselected patients with VTE treated with edoxaban for up to 18 months?
Real-world data from ETNA-VTE Europe demonstrates that edoxaban treatment for up to 18 months in unselected VTE patients is associated with low rates of VTE recurrence, major bleeding, and all-cause death, aligning with clinical trial results.
Answers are grounded in this paper and cite their sources.
Real-world edoxaban data may guide extended VTE therapy; leaves open optimal duration and risk stratification.
The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.The median age of the 2,644 patients was 65 years; 46.6% were female, and 22.8% had a history of VTE. The median treatment duration was 50.6 weeks (interquartile range: 23.4-77.7). VTE recurrence occurred in 100 patients (3.8% at an annual rate of 2.7%/year); 37 patients (1.4%) were on edoxaban at the time of the event, with a corresponding annualized rate of 1.6%/year. Major bleeding was experienced by 37 patients (1.4%) during edoxaban treatment, corresponding to an annualized rate of 1.5%/year. Overall, 95 patients died (3.6%; annualized rate 2.6%/year), with the majority for reasons other than VTE- and cardiovascular (CV)-related causes. Out of 15 deaths (1.9%; annualized rate 2.1%/year) that occurred during edoxaban treatment, 1 was related to VTE and 11 related to CV (annualized rate 0.0%/year and 0.5%/year).ETNA-VTE Europe provides evidence for the real-world effectiveness of edoxaban treatment (up to 18 months) based on a low rate of VTE recurrence, all-cause death, and major bleeding, and is aligned with the results of the randomized clinical trial reassuring the use of edoxaban in the treatment of VTE in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Agnelli et al. (2025) conducted an observational in Venous thromboembolism (VTE) (n=2,644). Edoxaban was evaluated on Recurrent VTE, major bleeding, and all-cause death. Real-world edoxaban treatment for up to 18 months in patients with VTE showed low rates of VTE recurrence, major bleeding, and all-cause death.
Synapse has enriched 10 related papers. Consider them for comparative context: